BRCA2 Mutation may Indicate Better Prognosis

A study of more than 3,500 women with ovarian cancer found that those with the BRCA2 mutation lived longer than those with the BRCA1 mutation or no mutation.

Of women with the BRCA2 mutation, more than 60% were alive five years after diagnosis, for women with the BRCA1 mutation that figure was 46%, and for those without a mutation it was 36%. Overall, 45% of women with ovarian cancer are alive five years after their diagnosis.

Read an article about the study here